ANNAPOLIS, Md., Sept. 26, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced the appointment of Brian A. Markison to the Company's Board of Directors, effective September 22, 2011.
Mr. Markison was recently appointed to the position of President and Chief Executive Officer for Nycomed U.S. which will be spun out from the acquisition of Nycomed A/S by Takeda Pharmaceuticals. Prior to joining Nycomed, A/S, Mr. Markison served as Chairman, President and Chief Executive Officer of King Pharmaceuticals, where he successfully led the Company through a $3.6 billion acquisition by Pfizer. Preceding his tenure at King, Mr. Markison held various executive leadership positions at Bristol-Myers Squibb, including, President of Oncology/ Virology and Oncology Therapeutics Network; Senior Vice President, Licensing & External Development and Mergers/Acquisitions; President, Neuroscience / Infectious Disease and Dermatology; and Vice President, Northeast Sales Primary Care.
"It is with great pleasure that we welcome Brian to PharmAthene's Board of Directors," remarked Mitchel Sayare, Ph.D., Chairman of the Board of PharmAthene. "With more than 30 years of distinguished service in the pharmaceutical industry in a variety of executive leadership roles, Brian's breadth of industry knowledge and experience will be an invaluable asset to PharmAthene as we chart the next phase of our Company's evolution towards commercial success."
"I am delighted to join the Board of PharmAthene, particularly at this transformative time in the company's history," commented Mr. Markison. "With potential revenues beginning as soon as 2012 based upon a 50/50 profit split of worldwide sales of SIGA Technologies' innovative smallpox
|SOURCE PharmAthene, Inc.|
Copyright©2010 PR Newswire.
All rights reserved